Pre-biopsy multiparametric magnetic resonance imaging improves the detection of clinically significant prostate cancer in biopsy-naive patients but does not appear to remove the need for systematic biopsy, MRI-FIRST study data show.
Treatment with radical prostatectomy plus adjuvant external beam radiotherapy and androgen deprivation therapy can offer equivalent survival outcomes to a nonsurgical approach in patients with high-risk prostate cancer, research shows.
Men with a new diagnosis of nonmetastatic prostate cancer say they would accept small reductions in survival odds if that meant fewer side effects and an improved quality of life, suggests the COMPARE study.
In patients undergoing radical therapy for cancer, an 8-week run-in period of aspirin is acceptable and well tolerated, and could reduce the risk for nonadherence and participant attrition in adjuvant and prevention trials, say researchers.
The latest results from the STAMPEDE trial do not show an additional overall survival benefit with radiotherapy for men undergoing androgen deprivation therapy with or without docetaxel for newly diagnosed metastatic prostate cancer.
Men with metastatic castration-resistant prostate cancer who are beginning treatment with abiraterone acetate plus prednisone may not need luteinizing hormone-releasing hormone therapy, suggest exploratory findings presented at the ESMO 2018 Congress in Munich, Germany.
An updated analysis of the NRG/RTOG 9413 trial shows that the benefits of whole pelvic radiotherapy plus neoadjuvant hormonal therapy persist in the long term in patients with intermediate- or high-risk localised prostate cancer.
Prostate-specific antigen-based screening may lead to a modest reduction in prostate cancer-specific mortality but has no effect on overall survival, say the authors of a meta-analysis published in The BMJ.
The addition of apalutamide to androgen deprivation therapy has no detrimental effect on health-related quality of life in men with nonmetastatic castration-resistant prostate cancer, an analysis of data from the SPARTAN trial shows.
A phase II proof-of-concept study has shown that clinically stable patients with metastatic castration-resistant prostate cancer and limited disease progression during treatment with abiraterone acetate plus prednisone can experience biochemical and radiologic responses following a steroid switch to dexamethasone.
Intensity-modulated radiation therapy using a moderately hypofractionated, dose-escalated regimen may control localized prostate cancer better than a conventional regimen while shortening treatment duration, a phase III trial suggests.
The ESMO Translational Research and Precision Medicine Working Group has proposed a classification system that orders the value of molecular aberrations as oncologic clinical targets based on the supporting evidence available.
Phase III trial findings suggest that men who require radical prostatectomy for localised prostate cancer achieve similar functional outcomes at 2 years, regardless of whether they undergo robot-assisted laparoscopic surgery or an open radical retropubic procedure.
The PD-1 inhibitor pembrolizumab shows antitumor activity in patients with previously treated metastatic castration-resistant prostate cancer, indicate results from the KEYNOTE-028 and KEYNOTE-199 trials.
Source:
Ann Oncol 2018; doi:10.1093/annonc/mdy232, ASCO Annual Meeting 2018; Chicago, Illinois, USA
Research published in JAMA Oncology points to the efficacy of a prostate-specific membrane antigen-directed docetaxel-containing nanoparticle in patients with metastatic castration-resistant prostate cancer.
Researchers have used a protein-based assay to confirm the validity of nuclear-localized androgen receptor splice variant 7 protein as a predictor of response to therapy for metastatic castration-resistant prostate cancer.
Two studies reported at the ASCO Annual Meeting 2018 show that Black men with metastatic castration-resistant prostate cancer fare as well as White men, if not better, when treated with abiraterone or chemotherapy in the clinical trial setting.
Addition of olaparib to abiraterone is associated with increased radiographic progression-free survival in unselected patients with metastatic castration-resistant prostate cancer, show study findings.
Prospective data confirm use of the automated Bone Scan Index as an independent prognostic marker of survival and other clinical outcomes in men with metastatic castration-resistant prostate cancer, researchers report.